The VxP Pharma platform has been extremely successful for us, and for our global clients. Biologics are a growing part of our portfolio, so the creation of VxP Biologics is a natural extension of both our service offering, and the VxP brand.
Indianapolis, Indiana (PRWEB) April 14, 2016
VxP Biologics, Inc. provides comprehensive contract development, and cGMP manufacturing of biologics, at its US-FDA audited facilities in the United States, as well as at its US-FDA audited cGMP facility in India.
Service areas include biologics process development and manufacturing, recombinant DNA engineering, cell line development, protein sciences (purification and crystallography), in-vivo pharmacology and toxicology, as well as cGMP antibody generation. All VxP facilities are US-FDA audited, and are currently serving the global pharmaceutical and biotech industry.
VxP Pharma was founded in 2010 as CRO Solutions, Inc., a sales representation agency representing global Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) from a business development and marketing standpoint. VxP Pharma was launched in 2014 as a platform to promote the combined services of all CRO Solutions clients under a single brand. VxP offers its services to research and development scientists at pharma and biotech companies worldwide, and has a staff of full-time business development representatives covering all major markets, as well as inside sales, technical support, internet marketing, and operations support.
VxP Pharma CEO Raymond E Peck says, “The VxP Pharma platform has been extremely successful both for us, and for our global clients. Biologics has become a growing part of our portfolio, so we feel that the creation of VxP Biologics is a natural extension of our service offering, and of our VxP brand.”
VxP is headquartered in Indianapolis, Indiana. To find out more, please visit: http://www.vxpbiologics.com.
